RX

RX Co., Ltd. (formerly RemedyX) is a South Korean biotechnology company dedicated to developing innovative gene therapies for rare and incurable diseases. The company's core strength lies in its proprietary RX-AAV platform, which focuses on engineering novel Adeno-associated virus capsids with enhanced tissue tropism and reduced pre-existing immunity. Its current pipeline includes promising candidates for Duchenne Muscular Dystrophy (DMD), Hemophilia A, and Hemophilia B, all utilizing optimized viral vectors for efficient gene delivery. Beyond neuromuscular and hematological disorders, RX is expanding its research into ophthalmic and central nervous system diseases. By integrating advanced capsid design with precise gene expression control, the company aims to provide definitive treatments for patients with limited therapeutic options. RX is actively seeking global collaborations to accelerate the clinical transition of its gene therapy programs.